Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$269.42 +0.02 (+0.01%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$269.50 +0.08 (+0.03%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Illumina - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
7
Buy
10

Based on 19 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 7 have given a hold rating, and 10 have given a buy rating for ILMN.

Consensus Price Target

$234.41
-12.99% Downside
According to the 19 analysts' twelve-month price targets for Illumina, the average price target is $234.41. The highest price target for ILMN is $310.00, while the lowest price target for ILMN is $113.00. The average price target represents a forecasted downside of -12.99% from the current price of $269.42.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
Hold
7 Hold rating(s)
6 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$234.41$199.13$156.88$115.25
Forecasted Upside-12.99% Downside-26.25% Downside-17.20% Downside15.12% Upside
Consensus RatingHoldHoldHoldHold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaHealthcare CompaniesBroader Market
Consensus Rating Score
2.42
2.32
2.53
Consensus RatingHoldHoldModerate Buy
Predicted Upside-12.99% Downside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent ILMN News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/23/2026
Stephens logo
Stephens
2 of 5 stars
 Reiterated RatingOverweight ➝ Equal Weight$275.00+2.02%
10/19/2026
Kyle Mikson
4 of 5 stars
Boost TargetHold$205.00 ➝ $300.00+14.27%
10/13/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Dan Brennan
Dan Brennan
5 of 5 stars
Boost TargetHold$210.00 ➝ $270.00+0.35%
10/7/2026Boost TargetUnderweight$160.00 ➝ $200.00-26.88%
10/5/2026Boost TargetOutperform$230.00 ➝ $310.00+12.36%
10/1/2026Boost TargetBuy$226.00 ➝ $305.00+12.33%
9/29/2026Boost TargetOutperform$220.00 ➝ $300.00+11.63%
9/28/2026Boost TargetOverweight$225.00 ➝ $305.00+12.96%
9/9/2026UpgradeNeutral ➝ Buy$135.00 ➝ $260.00+23.19%
9/3/2026Boost TargetBuy$180.00 ➝ $235.00+9.48%
9/1/2026 DowngradeStrong-Buy ➝ Hold
8/31/2026 Reiterated RatingHold (C)
8/5/2026 DowngradeHold
8/3/2026Boost TargetSell$95.00 ➝ $113.00-44.90%
7/31/2026Reiterated RatingMarket Perform$215.00+4.83%
7/31/2026Boost TargetOverweight$220.00 ➝ $230.00+14.36%
7/31/2026Boost TargetBuy$155.00 ➝ $225.00+13.72%
7/6/2026 Reiterated RatingOutperform
5/14/2026 UpgradeNeutral ➝ Outperform$155.00+6.90%
2/6/2026Set Target$137.00+13.26%
8/4/2025Boost TargetEqual Weight$100.00 ➝ $105.00+8.45%
7/11/2025DowngradeSector Outperform ➝ Sector Perform$125.00+24.94%
2/28/2025DowngradeStrong-Buy ➝ Hold$100.00+18.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:16 PM ET.


Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 24, 2026. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina, Inc. recently launched three early-access capabilities for its BioInsight Platform, including Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts, which expand the company's AI-driven variant prioritization and genomic-data workflow offerings, potentially increasing the strategic importance of its software and data services beyond traditional hardware and consumables.
  • The company demonstrated strong financial performance in its most recent reported quarter, with earnings per share of $1.31 exceeding the consensus estimate of $1.23 and revenue of $1.16 billion surpassing analyst expectations of $1.13 billion, indicating robust operational execution and a 9.4% year-over-year revenue increase.
  • Illumina, Inc. has raised its full-year 2026 earnings per share guidance to a range of $5.30 to $5.40, which is above the consensus estimate of $5.23, signaling management confidence in sustained growth driven by strong clinical demand and the adoption of its NovaSeq X sequencing systems.
  • Several major institutional investors have recently increased their stakes in the company, including Robeco Institutional Asset Management B.V., which boosted its position by 52.5% in the third quarter, and BlackRock Inc., which acquired a new stake valued at approximately $3.37 billion, reflecting significant institutional confidence in the stock's long-term potential.
  • The stock is currently trading at $269.42, which is well above its 50-day simple moving average of $242.35 and its 200-day simple moving average of $191.10, suggesting strong recent momentum and a positive technical trend that may attract further investor interest.

Illumina
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Stephens recently downgraded Illumina, Inc. from an "overweight" rating to an "equal weight" rating, reflecting a more cautious view of the stock's risk-reward profile and reducing a potential source of buying pressure from a major research firm.
  • Insiders have been consistently selling shares, with Director Keith Meister selling over 3 million shares in the past six months for an estimated $591 million, and other executives also making sales, which may signal a lack of confidence from those with the most direct knowledge of the company's operations.
  • The stock has experienced volatility due to broader sector sentiment, as it recently fell alongside other AI and genomics-related stocks in a broad technology selloff, indicating that its performance is susceptible to external market forces beyond company-specific news.
  • Despite strong clinical demand, the company faces persistent weakness in research markets, which could limit overall growth potential and create uncertainty for investors who are relying on broad-based demand across all customer segments.
  • The current price-to-earnings ratio of 52.31 is relatively high compared to the broader market, which may limit upside potential if the company fails to meet its elevated earnings expectations or if market sentiment shifts negatively toward high-growth biotechnology stocks.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $234.41, with a high forecast of $310.00 and a low forecast of $113.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

According to analysts, Illumina's stock has a predicted downside of -12.99% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 3 downgrades and 2 upgrades by analysts.

Analysts like Illumina more than other "healthcare" companies. The consensus rating score for Illumina is 2.42 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how ILMN compares to other companies.


MarketBeat monitors more than a dozen sources for Illumina analyst ratings, with the most recent rating issued on 10/23/2026.
From Our Partners